The FDA clearance of the Accelerate Arc system is a significant regulatory milestone for Accelerate Diagnostics. This approval allows the company to market its innovative platform, which can significantly reduce the time needed for microbial identification in sepsis cases. This advancement is likely to enhance the company's market position and could lead to increased adoption of its products, positively impacting its stock price in the short term.